Contact Shane Miller at 310-828-0061
Florida
GOG 0136 – Acquisition of Human GynecologicalSpecimens to be Used in Studying the Causes, Diagnosis, Prevention andTreatment of Cancer.
Contact Cami Kulwicki at 239-334-6626
GOG 0170-N – A Phase II Evaluation of aUrokinase-Derived Peptide (A6) (IND#64,298) in the Treatment of Persistent or Recurrent Epithelial Ovarian,Fallopian Tube or Primary Peritoneal Carcinoma.
Contact Cami Kulwicki at 239-334-6626
GOG 0210– A Molecular StagingStudy of Endometrial Carcinoma.
Contact Cami Kulwicki at 239-334-6626
GOG 0212 – A Randomized Phase III Trial ofMaintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxelor CT-2103 (IND# 70,177) Versus No Treatment Until Documented Relapse in Womenwith Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer who Achievea Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.
Contact Cami Kulwicki at 239-334-6626
GOG 0213 – A Phase III Randomized Controlled Clinical Trial ofCarboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC#704865, IND#7921) Followed by Bevacizumab and Cytoreductive Surgery in Platinum-Sensitive,Recurrent Ovarian, Peritoneal Primary, and Fallopian Tube Cancer.
Contact Cami Kulwicki at 239-334-6626
GOG 0249 – A Phase III Trial of PelvicRadiation Therapy Versus Vaginal Cuff Brachytherapy Followed byPaclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early StageEndometrial Carcinoma.
Contact Cami Kulwicki at 239-334-6626
21C-2007-02 - A Phase II Trial of StereotacticBody Radiation Therapy (SBRT) in the Treatment of Patients with RecurrentGynecologic Malignancy.
Contact Cami Kulwicki at 239-334-6626
TCREG-001-00-V2-1209-The Caris Registry Protocol: ARegistry of the Target Now® Test Results (Biomarker Expression Patterns) forEvaluation of Correlation with Clinical Outcomes for Cancer Patients. Contact CamiKulwicki at 239-334-6626
EC-FV-06-Arandomized double-blind phase 3 trial comparing EC145 and pegylated liposomaldoxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in Participants withplatinum-resistant ovarian cancer.
Contact Cami Kulwicki at 239-334-6626
21C-2006-01 - A Phase II Trial of StereotacticBody Radiation Therapy (SBRT) with or without Intensity Modulated RadiationTherapy (IMRT) in the Treatment of Patients with Clinically Confined ProstateAdenocarcinoma.
East Coast FL - Contact Peter Clark at 954-724-8500
West Coast FL - Contact Rudi Ross at 239-938-9315
21C-2010-05 - A Randomized trial of Music Therapyin Patients Undergoing Bone Marrow Procedures
Contact JaneSteeley at 1-800-335-4839
Ferring CS37-A randomized, controlled, open-labeltrial of Degarelix intermittent therapy vs continuous androgen deprivationtherapy with Leuprolide or Degarelix in patients with carcinoma of the prostatewith biochemical failure after localized therapy.
Contact PamelaBattle at 239-689-8800 ext. 236
PfizerA0221095 - A12-week, phase 4, randomized, double-blind, placebo controlled, parallel group,multicenter trial in overactive bladder subjects to confirm the efficacy of 8mg
Fesoterodine compared to 4 mgFesoterodine
ContactPamela Battle at 239-689-8800 ext. 236
Allergan GMA-SXR-09-004 – A multi-center, double-blind,placebo-controlled, trial of Sanctura XR 60 mg daily in female OAB patients onmultiple concomitant medications refractory to Detrol LA 4 mg daily
ContactPamela Battle at 239-689-8800 ext. 236
BN ImmunoTherapeutics BNIT-PRV-30- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF inMen With Asymptomatic or Minimally SymptomaticMetastatic, Castrate-Resistant Adenocarcinoma of the Prostate
ContactPamela Battle at 239-689-8800 ext. 236
Medifocus,Inc. 102-00-301 -A randomized pivotal trial to assess the safety and efficacy of preoperativefocused microwave thermotherapy plus preoperative chemotherapy versuspreoperative chemotherapy alone for cytoreduction of large breast cancer infemale patients with intact breast
Contact Susann Damiano – 954-345-2718
APC-10U1101 - A Randomized, Multi-center, Prospective, Double‐blind, Sham‐controlled Study to Evaluate theEfficacy of MuGardTM Mucoadhesive Oral Wound Rinse for the Amelioration of OralMucositis in Subjects Receiving Chemoradiation Therapy for the Treatment ofCancers of the Head and Neck.
Contact SondraMorrison at 941-308-1050 (Bradenton) or DanQuinn at 850-863-5294 (Fort WaltonBeach)
Michigan
21C-2006-01 - A Phase II Trial of StereotacticBody Radiation Therapy (SBRT) with or without Intensity Modulated RadiationTherapy (IMRT) in the Treatment of Patients with Clinically Confined ProstateAdenocarcinoma.
ContactStefanie Shepherd at 248-553-0606
APC-10U1101 - A Randomized, Multi-center, Prospective, Double‐blind, Sham‐controlled Study to Evaluate theEfficacy of MuGardTM Mucoadhesive Oral Wound Rinse for the Amelioration of OralMucositis in Subjects Receiving Chemoradiation Therapy for the Treatment ofCancers of the Head and Neck.
Contact StefanieShephard at 248-553-0606
North Carolina
APC-10U1101 - A Randomized, Multi-center, Prospective, Double‐blind, Sham‐controlled Study to Evaluate theEfficacy of MuGardTM Mucoadhesive Oral Wound Rinse for the Amelioration of OralMucositis in Subjects Receiving Chemoradiation Therapy for the Treatment ofCancers of the Head and Neck.
Contact ColetteMcKoy at 252-329-0025.
South Carolina
21C-2006-01 - A Phase II Trial of StereotacticBody Radiation Therapy (SBRT) with or without Intensity Modulated RadiationTherapy (IMRT) in the Treatment of Patients with Clinically Confined ProstateAdenocarcinoma.
Contact KarenPrice at 843-449-9415
Arizona
21C-2006-01 – (Pending) A Phase II Trial ofStereotactic Body Radiation Therapy (SBRT) with or without Intensity ModulatedRadiation Therapy (IMRT) in the Treatment of Patients with Clinically ConfinedProstate Adenocarcinoma.
Contact StevenFinkelstein, MD at 480-945-6896
21C-2007-02 - A Phase II Trial of StereotacticBody Radiation Therapy (SBRT) in the Treatment of Patients with RecurrentGynecologic Malignancy.
Contact Steven Finkelstein, MD at 480-945-6896